245 related articles for article (PubMed ID: 31724343)
1. Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
Dumitrescu TP; Peddiraju K; Fu C; Bakshi K; Yu S; Zhang Z; Tenorio AR; Spancake C; Joshi S; Wolstenholme A; Adkison K
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):189-202. PubMed ID: 31724343
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants.
Singh RP; Adkison K; Wolstenholme A; Hopking J; Wynne B
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):985-993. PubMed ID: 34265164
[TBL] [Abstract][Full Text] [Related]
3. The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Blackman AL; Heil EL; Devanathan AS; Pandit NS
Antivir Ther; 2020; 25(2):115-119. PubMed ID: 32341207
[TBL] [Abstract][Full Text] [Related]
4. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL; Deeks ED
Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
[TBL] [Abstract][Full Text] [Related]
5. Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.
Singh RP; Adkison KK; Baker M; Parasrampuria R; Wolstenholme A; Davies M; Sewell N; Brothers C; Buchanan AM
Pediatr Infect Dis J; 2022 Mar; 41(3):230-237. PubMed ID: 34817414
[TBL] [Abstract][Full Text] [Related]
6. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
Cento V; Perno CF
J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection.
Mehta R; Wolstenholme A; Di Lullo K; Fu C; Joshi S; Crauwels H; Givens N; Vanveggel S; Wynne B; Adkison K
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987139
[TBL] [Abstract][Full Text] [Related]
9. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
Yuen GJ; Lou Y; Thompson NF; Otto VR; Allsup TL; Mahony WB; Hutman HW
J Clin Pharmacol; 2001 Mar; 41(3):277-88. PubMed ID: 11269568
[TBL] [Abstract][Full Text] [Related]
10. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P; Stader F; Guidi M; Alves Saldanha S; Stoeckle M; Cavassini M; Battegay M; Buclin T; Decosterd LA; Marzolini C;
AIDS; 2020 Jan; 34(1):103-108. PubMed ID: 31490233
[TBL] [Abstract][Full Text] [Related]
12. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.
Anderson MS; Khalilieh S; Yee KL; Liu R; Fan L; Rizk ML; Shah V; Hussaini A; Song I; Ross LL; Butterton JR
Clin Pharmacokinet; 2017 Jun; 56(6):661-669. PubMed ID: 27699622
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.
Weller S; Chen S; Borland J; Savina P; Wynne B; Piscitelli SC
J Acquir Immune Defic Syndr; 2014 Aug; 66(4):393-8. PubMed ID: 24798770
[TBL] [Abstract][Full Text] [Related]
14. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
15. Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure.
Roskam-Kwint M; Bollen P; Colbers A; Duisenberg-van Essenberg M; Harbers V; Burger D
J Antimicrob Chemother; 2018 Sep; 73(9):2430-2434. PubMed ID: 29796595
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
Chandasana H; Singh R; Adkison K; Ait-Khaled M; Pene Dumitrescu T
Antimicrob Agents Chemother; 2024 May; 68(5):e0150423. PubMed ID: 38587380
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Kaimal A; Mirembe G; Tukamushabe P; Ategeka G; Hakim J; Mugerwa H; Siika A; Asienzo J; Castelnuovo B; Kiragga A; Kambugu A;
N Engl J Med; 2021 Jul; 385(4):330-341. PubMed ID: 34289276
[TBL] [Abstract][Full Text] [Related]
18. Rollout of dolutegravir-based antiretroviral therapy in sub-Saharan Africa and its public health implications.
Wilson HI; Mapesi H
Pan Afr Med J; 2020; 37():243. PubMed ID: 33552361
[No Abstract] [Full Text] [Related]
19. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425
[TBL] [Abstract][Full Text] [Related]
20. A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
Monif T; Reyar S; Tiwari HK; Tippabhotla SK; Khuroo A; Thudi NR; Ahmed S; Raghuvanshi R
Arzneimittelforschung; 2009; 59(2):104-8. PubMed ID: 19338141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]